Introduction
In cancer cells, a substantial amount of energy is produced by aerobic glycolysis and most of the incoming glucose is converted to lactate (Warburg effect) 1 . The lower rates of ATP generated by aerobic glycolysis are partially compensated by glutaminolysis. In this process, glutamine is converted to glutamate by glutaminase and further metabolized to α-ketoglutarate, which feeds into the tricarboxylic acid (TCA) cycle 2 . Glutamine also participates in the prevention of oxidative damage, and in the biosynthesis of nonessential amino acids, nucleotide and fatty acids 3 . Therefore, many tumor cells rely on glutamine to maximize their growth 4 and targeting the glutamine pathway is considered a promising strategy for treating cancer.
RhoA and RhoC are highly homologous GTPases (approximately 92% amino acid identity) that have each been implicated in glutamine metabolism [5] [6] [7] . RhoA has been better characterized than RhoC, however several studies have demonstrated that they present distinct functions in cancer. RhoA is frequently involved in cell cycle progression and migration, whereas RhoC is linked to metastasis and reduced cell survival 8, 9 .
RhoA inhibition in an epithelial mammalian cell model was synthetic lethal with Myc, a master regulator of glutamine metabolism 7 . Inhibition of RhoA induced apoptosis in Myc-transformed cells, which was reversed by exogenous α-ketoglutarate treatment. In addition, Myc was unable to elevate glutamate levels when the Rho subfamily was inhibited with C3 transferase Rho inhibitor, suggesting that Myc is dependent on the signaling mediated by Rho to supply the glutamine demands of transformation 7 . In NIH3T3 cells, the pharmacological inhibition of a specific splice variant of mitochondrial glutaminase (GLS1) was capable of reversing the transformation caused by the RhoGEF Dbl oncogenic protein 5 . Dbl has been shown to activate several Rho GTPases, including RhoA 10 . The colony forming ability of NIH3T3 cells transformed by overexpression of RhoC, Rac1 or Cdc42 was also blocked by GLS1 knockdown, indicating that inactivation of glutaminolysis was sufficient to prevent Rho GTPase-induced transformation 5 . Silencing of RhoC in inflammatory breast cancer cells markedly decreased glutamine uptake, without altering glucose uptake or lactate production. Regardless of the lower glutamine uptake, the cells remained dependent on glutamine. RhoC knockdown also increased glutamine synthetase, but did not alter GLS1 6 .
Despite these recent studies, the relative contributions of RhoA and RhoC in glutamine metabolism remain unclear. Here, we compare the roles of both proteins in glutamine dependency of prostate cancer cells by evaluating the effects of RhoA or RhoC activation and inactivation on the survival of prostate cancer cell lines cultured under glutamine deprivation.
Results
To measure the sensitivity of prostate cancer cells to glutamine deprivation, we 
Discussion
Reliance on glutamine varies substantially between different cancer cells. Some types of cells are highly sensitive to glutamine deprivation, while others do not require an exogenous source of this amino acid to survive 4 . Here we show that PC3 and LNCaP prostate cancer cells respond to glutamine reduction or deprivation mainly by decreased cell proliferation. However, the effects of glutamine deprivation on the cell cycle and apoptosis varied between these cell lines. PC3 and LNCaP cells were established from very different prostate tumors 11, 12 and diverge in their metastatic potential, gene expression profile and metabolism control 13, 14 . Therefore, our data are in accordance with other studies that showed that glutamine sensitivity is related to aggressiveness 15 , modulation of glucose metabolism and the status of other genes 16 .
It is interesting that PC3 cells and LNCaP cells show different patterns of
RhoA/RhoC activity depending on glutamine levels. Further studies are important to elucidate the roles of RhoA and RhoC in glutamine metabolism. Our findings add new insights regarding the participation of these two proteins in the sensitivity of prostate cancer cells to glutamine deprivation.
Materials and Methods

Cell culture
The human prostate cancer cell lines LNCaP and PC3 were acquired from ATCC (American Type Culture Collection, Philadelphia, USA). Cells were cultured in RPMI medium (Gibco) with 10% FBS and maintained in a humidified incubator at 37°C and 5% CO 2 . To evaluate the cellular response to glutamine deprivation, cells were grown in culture medium containing 10% FBS and different glutamine concentrations. 
MTT assays and determining cell number
Cell cycle analysis
Cell cycle was evaluated by flow cytometry, as previously described 29 . Briefly, the cells were collected, fixed in 70% ethanol and stored at 4°C for at least 4 hours. After washing in PBS, the samples were suspended in cell cycle buffer (0.1% Triton X-100, 10 mg/mL propidium iodide, 0.1 mg/mL RNase A) and incubated at 37°C for 30
minutes. Fluorescence was detected with a FACSCalibur (BD Biosciences) and ModFit
Software (BD Biosciences) was used to determine the proportions of cells in each cell cycle phase. Ten thousand events were acquired for each sample.
Rho GTPase activity assays
RhoA, Cdc42 and RhoC activities were determined by affinity precipitation assay, as previously described 18 . Briefly, cell lysates (25mM Hepes, pH 7.5, 150mM NaCl, 1%
Nonidet P-40, 10mM MgCl 2 , 1mM EDTA, 25mM NaF, 1mM Na3VaO4, 10μg/mL aprotinin, 100μM PMSF, and 10% glycerol) were incubated with the GST-RBD at 4°C
with rotation for 4 hours. After four washes, the pull down samples and total protein extracts were subjected to SDS-PAGE and western blotting analysis with specific antibodies.
Western blotting
Cells were lysed with protein extraction buffer containing 100 mM Tris (pH 7.6), 1%
Triton X-100, 150 mM NaCl, 0.1 mg Aprotinin, PMSF, 35 mg/mL, 10 mM Na3VO4, 100 mM NaF, 10 mM Na4P2O7 and 4 mM EDTA. The protein extracts were subjected to SDS-PAGE and western blotting analysis with specific primary antibodies: anti-LC3 
Stable transfection
GFP-fusions of wild type forms of RhoA (RhoA wt ) and RhoC (RhoC wt ) and dominant negative mutants of RhoA (RhoA N19 ) and RhoC (RhoC N19 ) (in EGFP) were transfected into PC3 cells. Briefly, the cells were transfected using jetPEI (Polyplus transfection), according to the manufacturer´s instructions. Cells expressing eGFP were used as control cells. Cells were then selected with 700µg/mL G418 (geneticin) for at least ten days then sorted for GFP using a FACsAria Fusion (Becton-Dickinson Biosciences).
Analysis of cellular morphology
Cell morphology was observed by fluorescence microscope through GFP detection.
Image J software (National Institutes of Health) was used to measure the cell area and circularity. Circularity was calculated as previously described 30 
Assessment of apoptosis
Apoptosis was determined with Annexin V Apoptosis Detection Kit (BD Biosciences), according to the manufacturer's instructions. All specimens were analyzed by a FACSCalibur (BD Biosciences) and at least ten thousand events were acquired for each sample.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). For comparisons, ANOVA test and Dunnett´s post-test were used. A P value <0.05 was considered as statistically significant. Bonferroni test was used to determine significance.
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